The legislation, the “Food and Drug Administration Safety and Innovation Act,” was written to reauthorize the FDA’s prescription drug user fee program, which allows the FDA to collect fees from drug manufacturers to support the agency’s operations.
Title X of the bill includes provisions to help prevent drug shortages, including a requirement that manufacturers notify the FDA when the production of certain drugs would be interrupted and a requirement that the Drug Enforcement Administration provides timely updates on drug quota increases to manufacturers.
The U.S. Senate will vote on the legislation this week, and the president is expected to sign the bill into law soon afterwards.
Related Articles on Anesthesia:
What Does Medicare’s 3-Day Payment Rule Mean for Anesthesia and Pain Practices?
Anesthesiologist to Serve Sixth Consecutive Term on AMA Board
University of Alabama Appoints Anesthesiology Professor Emeritus
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
